For individuals with T2D and ASCVD or kidney disease, monotherapy with an SGLT-2 inhibitor or GLP-1 receptor agonist, or combination therapy with proven cardiovascular benefits, is recommended. Here, SLC5A2 is linked to type 2 diabetes mellitus.